Condition 1: Uterine bleeding. Condition 2: Endometrial hyperplasia. Abnormal uterine and vaginal bleeding, unspecified Endometrial hyperplasia
Conditions
Interventions
Intervention 1: Control group: Receiving megestrol acetate tablets with a dose of 80 mg daily for 3 months. Intervention 2: Intervention group: receiving 1000 mg Gerdoheal capsules once daily for up t
Sponsors
Tabriz University of Medical Sciences
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Mothers in reproductive age with abnormal uterine bleeding without receiving hormonal drugs since 8 weeks ago
Exclusion criteria
Exclusion criteria: Patients with a history of cardiovascular disease, liver disease, kidney disease, pulmonary disease, high blood pressure, hematological disease, diabetes, hyperlipidemia, thromboembolism, chronic constipation, headache and dizziness, cancer and taking anticonvulsant and anticonvulsant drugs and nursing mothers
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Changes in the pathology of the uterine endometrium in terms of proliferative or hyperplasia. Timepoint: Before and after the intervention. Method of measurement: Pathological diagnostic evaluation by a skilled pathologist.;Drug side effects. Timepoint: After the intervention. Method of measurement: Assessing the presence or absence of known drug side effects. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactDr. Mehri Jafari Shobeiri
Tabriz University of Medical Sciences
Outcome results
None listed